MINODIAB Tablet Ref.[27643] Active ingredients: Glipizide

Glucose-6-phosphate dehydrogenase deficiency

Since glipizide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency. Treatment of patients with G6PD deficiency with sulfonylurea agents can lead to haemolytic anaemia and a non-sulfonylurea alternative should be considered.

Hypoglycaemia

All sulfonylurea agents are capable of producing severe hypoglycaemia. Renal or hepatic insufficiency may cause elevated blood levels of glipizide and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycaemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycaemic action of glucose-lowering drugs.

Hypoglycaemia may be difficult to recognise in the elderly, and in people who are taking beta-adrenergic blocking drugs (see section 4.5). Hypoglycaemia is more likely to occur when caloric- intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of control of blood glucose

When a patient stabilised on a diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue glipizide and administer insulin.

The effectiveness of any oral hypoglycaemic drug, including glipizide, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of diabetes or due to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.

Renal and Hepatic Disease

The pharmacokinetics and/or pharmacodynamics of glipizide may be affected in patients with impaired renal or hepatic function. If hypoglycaemia should occur in such patients, it may be prolonged and appropriate management should be instituted.

Information for Patients

Patients should be informed of the potential risks and advantages of glipizide and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycaemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Laboratory Tests

Blood and urine glucose should be monitored periodically. Measurement of glycosylated haemoglobin may be useful.

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption should not take this medicine.

The following products are likely to increase the hypoglycaemic effect:

Contraindicated combinations:

Miconazole:

Increase in hypoglycaemic effect, possibly leading to symptoms of hypoglycaemia or even coma.

Inadvisable combinations:

Nonsteroidal Anti-inflammatory Drugs (e.g. phenylbutazone):

Increase in hypoglycaemic effect of sulfonylureas (displacement of sulfonylurea binding to plasma proteins and/or decrease in sulfonylurea elimination).

Alcohol:

Increase in hypoglycaemic reaction, which can lead to hypoglycaemic coma.

Combinations requiring precaution:

Fluconazole:

Increase in the half-life of the sulfonylurea, possibly giving rise to symptoms of hypoglycaemia.

Voriconazole:

Although not studied, voriconazole may increase the plasma levels of sulfonylureas, (e.g. tolbutamide, glipizide and glyburide) and therefore cause hypoglycaemia. Careful monitoring of blood glucose is recommended during co-administration.

Salicylates (acetylsalicylic acid):

Increase in hypoglycaemic effect by high doses of acetylsalicylic acid (hypoglycaemic action of the acetylsalicylic acid).

Beta-blockers:

All beta-blockers mask some of the symptoms of hypoglycaemia (i.e. palpitations and tachycardia). Most non cardio selective beta-blockers increase the incidence and severity of hypoglycaemia.

Angiotensin-converting Enzyme Inhibitors:

The use of angiotensin-converting enzyme inhibitors may lead to an increased hypoglycaemic effect in diabetic patients treated with sulfonylureas.

Cimetidine:

The use of cimetidine may be associated with a reduction in post prandial blood glucose in patients treated with glipizide.

The hypoglycaemic action of sulfonylureas, in general may also be potentiated by monoamine oxidase inhibitors, quinolones and drugs that are highly protein bound, such as sulfonamides, chloramphenicol, probenecid, coumarins and fibrates.

When such drugs are administered to (or withdrawn from) a patient receiving glipizide, the patient should be observed closely for hypoglycaemia (or loss of control).

The following products could lead to hyperglycaemia:

Inadvisable combinations:

Danazol:

Diabetogenic effect of danazol. If it cannot be avoided, warn the patient and step up self monitoring of blood glucose and urine. Possibly adjust the dosage of antidiabetic agent during treatment with danazol and after its discontinuation.

Combinations requiring precaution:

Phenothiazines (e.g. chlorpromazine) at High Doses (>100 mg/day of chlorpromazine):

Elevation in blood glucose (reduction in insulin release).

Corticosteroids:

Elevation in blood glucose.

Sympathomimetics (e.g. ritodrine, salbutamol, terbutaline):

Elevation in blood glucose due to beta-2-adrenoceptor stimulation.

Progestogens:

Diabetogenic effects of high-dose progestogens. Warn the patient and step up self-monitoring of blood glucose and urine. Possibly adjust the dosage of antidiabetic agent during treatment with the neuroleptics, corticoids or progestogen and after discontinuation.

Other drugs that may produce hyperglycaemia and lead to a loss of control include the thiazides and other diuretics, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, calcium channel blocking drugs, and isoniazid.

When such drugs are administered to (or withdrawn from) a patient receiving glipizide, the patient should be observed closely for hypoglycaemia

Pregnancy

Glipizide is contraindicated in pregnancy.

Glipizide was found to be mildly fetotoxic in rat reproductive studies. No teratogenic effects were found in rat or rabbit studies.

Prolonged severe hypoglycaemia (4- 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Breast-feeding

No data are available on secretion into breast milk. Therefore glipizide is contraindicated in lactation.

The effect of glipizide on the ability to drive or operate machines has not been studied; however, there is no evidence to suggest that glipizide may affect these abilities. Patients should be aware of the symptoms of hypoglycaemia and be careful about driving and the use of machines, especially when optimum stabilisation has not been achieved, for example during the change-over from other medications or during irregular use.

The majority of side effects have been dose related, transient, and have responded to dose reduction or withdrawal of the medication. However, clinical experience thus far has shown that, as with other sulfonylureas, some side effects associated with hypersensitivity may be severe and deaths have been reported in some instances.

The reported adverse reactions, which may possibly be associated with glipizide, are listed in the following table by system organ class and frequency group: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from available data).

Blood and lymphatic system disorders

Not known: Leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, pancytopenia

Metabolism and nutrition disorders

Common: Hypoglycaemia

Not known: Hyponatremia

Psychiatric disorders

Not known: Confusional state^#

Nervous system disorders

Uncommon: Dizziness^#, somnolence^#, tremor^#

Not known: Headache^#

Eye disorders

Uncommon: Vision blurred^#

Not known: Diplopia^#, visual impairment^#, visual acuity reduced^#

Gastrointestinal disorders

Common: Nausea^$, diarrhoea^$, abdominal pain and upper^$, abdominal pain

Uncommon: Vomiting

Not known: Constipation^$

Hepatobiliary disorders

Uncommon: Jaundice cholestatic^†

Not known: Hepatic function abnormal, hepatitis

Skin and subcutaneous tissue disorders

Uncommon: Eczema^‡

Not known: Dermatitis allergic^‡, erythema^‡, rash morbilliform^‡, rash maculopapular^‡, urticaria^‡, pruritus^‡, photosensitivity reaction

Congenital, familial and genetic disorders

Not known: Porphyria non-acute

General disorders and administration site conditions

Not known: Malaise^#

Investigations

Not known: Aspartate aminotransferase increased^§, blood lactate dehydrogenase increased^§, blood alkaline phosphatase increased^§, blood urea increased^§, blood creatinine increased^§

^# This is usually transient and do not require discontinuance of therapy; however, they may also be symptoms of hypoglycaemia.
^$ Appear to be dose related and usually disappear on division or reduction of dosage.
^† Discontinue treatment if cholestatic jaundice occurs.
^‡ They frequently disappear with continued therapy. However, if they persist, the drug should be discontinued.
^§ The relationship of these abnormalities to glipizide is uncertain, and they have rarely been associated with clinical symptoms.

Aplastic anaemia and disulfiram-like reactions have been reported with other sulfonylureas.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Not applicable.